Momenta Pharmaceuticals, a biotechnology company based in Cambridge, Massachusetts, has entered into a non-exclusive license agreement with BioFactura, a Frederick, Maryland-based biopharmaceutical research and manufacturing company, relating to one of the biosimilar product candidates that Momenta is developing. As part of this non-exclusive license agreement, BioFactura is developing a cell line using its NS0-based StableFast biomanufacturing platform, a system to generate stable cell lines.

The companies are working together to further optimize productivity. Momenta has the right to obtain an exclusive research and commercial license to StableFast for clinical development and commercial manufacture of the undisclosed biosimilar product candidate.

BioFactura develops and commercializes biosimilars.

Source: BioFactura